Target intelligence / Profile preview

Interleukin-7 receptor (IL-7R) (IL-7R)

Target
IL-7R
Molecular classification
Receptor, Cytokine receptor, Type I cytokine receptor family
01

Overview

The Interleukin-7 receptor (IL-7R) is a critical type I cytokine receptor primarily expressed on the surface of T cells and their precursors, where it mediates signals essential for lymphocyte development and homeostasis [UniProt: P16871]. The functional receptor is a heterodimer composed of the IL-7 receptor alpha subunit (IL-7Rα, also known as CD127) and the common gamma chain (γc, or CD132) [PubMed: 21930775]. Binding of the IL-7 ligand to this receptor activates the JAK/STAT and PI3K/Akt signaling pathways, promoting cell survival, proliferation, and V(D)J recombination during T-cell maturation [NCBI: 3575]. Genetic defects in IL-7R lead to severe combined immunodeficiency (SCID), while its over-activation is a hallmark of T-cell acute lymphoblastic leukemia (T-ALL) and various autoimmune diseases such as multiple sclerosis and rheumatoid arthritis [PubMed: 28255105]. In drug development, IL-7R is targeted by monoclonal antibodies like lusvertikimab to treat inflammatory diseases by blocking IL-7 and TSLP signaling [ClinicalTrials.gov: NCT04882007]. Conversely, recombinant IL-7 (e.g., CYT107) is used as an agonist to enhance immune recovery in patients with lymphopenia or chronic infections [PubMed: 25035958].

Other names
CD127IL-7RAInterleukin-7 receptor subunit alphaCDw127
02

Mechanism of action

Antagonism of the IL-7 receptor alpha subunit (CD127) to block IL-7 and TSLP signaling pathways, or agonism via recombinant IL-7 to stimulate T-cell production and survival.

03

Biological functions

Immune responseCell proliferationCell survivalT-cell developmentLymphopoiesis
04

Disease associations

CancerInflammationAutoimmune diseaseInfection
05

Safety considerations

Risk of severe lymphopeniaIncreased susceptibility to opportunistic infectionsPotential for cytokine release syndromeRisk of exacerbating autoimmune conditionsPotential for leukemic transformation
06

Interacting drugs

Lusvertikimab

3 more in the full profile.

07

Biomarkers

CD127 surface expressionSTAT5 phosphorylation (pSTAT5)Absolute lymphocyte count (ALC)T-cell receptor excision circles (TRECs)

Beyond the preview

Go deeper on Interleukin-7 receptor (IL-7R) (IL-7R).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interleukin-7 receptor (IL-7R) (IL-7R).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call